CurrentRegence BlueCross BlueShieldPolicy 166

Intensity Modulated Radiotherapy (IMRT) for Breast Cancer

Customize your policy alerts

Sign up for regence Policy 166 alerts

Get alerted when Policy 166 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs when IMRT for breast cancer may be considered medically necessary, including definitive post-lumpectomy and adjuvant post-mastectomy treatment. Prior authorization is required.

Policy Summary

PayerRegence BlueCross Blue Shield

PolicyIntensity Modulated Radiotherapy (IMRT) for Breast Cancer

Policy CodePolicy 166

Change TypeNo material change

Effective DateJanuary 1, 2026

Last ReviewDec 1, 2025

Next Review DateSeptember 1, 2026

Key ActionSubmit prior authorization for breast cancer IMRT with documentation supporting the applicable medical-necessity pathway.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2 pathwaysMedical-necessity pathways

10%Required cardiac dose reduction

≤16 fractionsPreferred post-lumpectomy fractionation

≤28 fractionsPreferred post-mastectomy fractionation

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentRegence BlueCross BlueShieldPolicy 166

Intensity Modulated Radiotherapy (IMRT) for Breast Cancer

Customize your policy alerts

Sign up for regence Policy 166 alerts

Get alerted when Policy 166 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs when IMRT for breast cancer may be considered medically necessary, including definitive post-lumpectomy and adjuvant post-mastectomy treatment. Prior authorization is required.

Policy Summary

PayerRegence BlueCross Blue Shield

PolicyIntensity Modulated Radiotherapy (IMRT) for Breast Cancer

Policy CodePolicy 166

Change TypeNo material change

Effective DateJanuary 1, 2026

Last ReviewDec 1, 2025

Next Review DateSeptember 1, 2026

Key ActionSubmit prior authorization for breast cancer IMRT with documentation supporting the applicable medical-necessity pathway.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2 pathwaysMedical-necessity pathways

10%Required cardiac dose reduction

≤16 fractionsPreferred post-lumpectomy fractionation

≤28 fractionsPreferred post-mastectomy fractionation

Comparative planning documentation

Medical Necessity Criteria

Single-Criterion Medical Necessity

IMRT may be considered medically necessary for breast cancer treatment—either definitive post-lumpectomy or adjuvant post-mastectomy—when ANY of the following applies:

ANY of the following

There is documented prior radiation treatment to the planned target volume.
IMRT is used to deliver accelerated partial breast irradiation (APBI).

Combined IMRT-Need and Treatment Criteria

IMRT may be considered medically necessary for breast cancer treatment—either definitive post-lumpectomy or adjuvant post-mastectomy—when BOTH the IMRT-need criterion and the applicable treatment criterion are met.

ALL of the following

The need for IMRT is demonstrated by ANY of the following
- Documentation demonstrates the need for IMRT to minimize focal hot spot(s) within the breast tissue from greater than 10% to less than 10% of the prescribed dose.
- Documentation demonstrates that IMRT planning can achieve a 10% or greater reduction in mean dose to the heart, left ventricle, left main coronary artery, or left anterior descending artery.>= 10% reduction in mean dose
- Comparative 3D versus IMRT dose/volume histograms are submitted in color, together with a summary analysis—preferably in table format with the preauthorization request—demonstrating that published dose/volume constraints for organs at risk can be met only through IMRT. Quality assurance procedures are not required for preauthorization.
The treatment criterion is met by ANY of the following
- There is documentation of mixed connective tissue disorder or collagen vascular disease.
- Treatment is post-lumpectomy and ALL of the following apply
  - Treatment is directed to ANY of the following
    The whole breast plus the regional nodes, with any number of fractions.
    The whole breast when regional nodes are NOT to be treated, and ALL of the following apply
    The fractionation requirement is met by ANY of the following
    Ultra- or moderate hypofractionation is planned or delivered, with no more than 16 fractions, with or without 4 to 8 boost treatments.<= 16 fractions

Not Medically Necessary

The following treatment is not medically necessary:

IMRT for the treatment of breast cancer that does not meet the medical-necessity criteria above.

IMRT Medical Necessity

IMRT to deliver breast irradiation may be considered medically necessary in select patients when the policy criteria are met. The available evidence suggests that IMRT may provide clinical outcomes comparable to 3D-conformal radiotherapy while reducing cardiac dose in left-sided breast cancer, avoiding or minimizing breast hot spots, and decreasing acute skin toxicity.

Select-patient breast cancer treatment meeting the policy's single-criterion pathway or combined IMRT-need and treatment criteria.

Guideline-Supported Use

The following clinical contexts are supported by cited NCCN and ASTRO guidance:

Guideline-supported contexts

NCCN recommends hypofractionated whole-breast irradiation, generally 40–42.5 Gy in 15–16 fractions; selected cases may receive 45–50.4 Gy in 25–28 fractions.
NCCN includes IMRT among treatment options for post-mastectomy radiation therapy (PMRT).
NCCN describes regional-node radiation schedules of 46–50 Gy with conventional fractionation or 39–42 Gy with moderate fractionation, similar to PMRT and whole-breast schedules.
NCCN recommends using dose-volume histograms to evaluate dose, normal-tissue constraints—including heart and lung—and planning target volumes.
NCCN recommends APBI for individuals who are BRCA negative and meet the 2023 ASTRO criteria; the preferred APBI regimen is 30 Gy in 5 fractions delivered every other day, which is delivered with IMRT.

Fractionation Selection

Hypofractionation—fewer treatment sessions with higher doses—is supported by evidence and preferred by clinical practice guidelines in the following contexts:

Preferred fractionation contexts

Whole-breast irradiation after lumpectomy: 15–16 fractions, with or without a tumor-bed boost.
Chest-wall irradiation after mastectomy: 25–28 fractions, with or without a scar boost.
Post-mastectomy radiation without breast reconstruction: moderate hypofractionation of 266–267 cGy per fraction for 15–16 fractions.
Post-mastectomy radiation with breast reconstruction: moderate hypofractionation is preferred over conventional fractionation.
APBI: 30 Gy in 5 fractions delivered every other day is the preferred NCCN regimen and is delivered with IMRT.

IMRT is not medically necessary for breast cancer treatment except for the select group of patients identified by the policy criteria.

IMRT is not medically necessary when breast cancer treatment does not meet the stated medical-necessity criteria.

When the applicable policy criteria are not met, IMRT is not medically necessary because it has not been shown to improve net health outcomes compared with other treatment modalities.

In clinical contexts for which the policy criteria indicate that hypofractionation is preferred, conventionally fractionated IMRT is not medically necessary when no clinical rationale is provided for using the longer conventional regimen.

Billing and Procedure Codes

CPTCPT

77399	Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services; the correct code for image fusion performed to provide enhanced delineation of target and normal critical structures, considered part of treatment planning.
77301	Intensity modulated radiotherapy plan, including dose volume histograms for target and critical structure partial tolerance specification.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple (Deleted 01/01/2026).

HCPCSHCPCS

77386	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow; complex (Deleted 01/01/2026).
G6015	Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session (Deleted 01/01/2026).

Authorization and Documentation Requirements

Prior Authorization

Submit IMRT prior authorization

Prior authorization is required for review of breast cancer IMRT. Submit documentation supporting the applicable medical-necessity pathway; Criterion II requests also require comparative 3D-versus-IMRT planning information and analysis.

Documentation Required

Submit complete clinical records

Submit provider consultation and relevant follow-up notes, relevant pathology reports, and relevant imaging reports documenting that the medical-necessity criteria are met.

Provider consultation and relevant follow-up notes
Relevant pathology reports
Relevant imaging reports

Clinical Background

Intensity-modulated radiotherapy (IMRT) uses computer-based inverse planning to determine beam arrangements and intensity patterns that shape the prescribed dose around the treatment target. The treatment uses multiple shaped fields and modulated radiation beams, typically controlled with a multileaf collimator, to optimize dose distribution while limiting exposure to surrounding normal tissues and organs at risk.

Terms and Treatment Techniques

Organs at risk

DefinitionNormal tissues whose radiation sensitivity may significantly influence treatment planning and/or prescribed radiation dose.

Clinical significanceThese tissues may be particularly vulnerable to clinically important complications from radiation toxicity.

Planning relevanceOrgan-at-risk sensitivity can affect the treatment plan and the prescribed radiation dose.

Intensity-modulated radiotherapy (IMRT)

DefinitionA radiation therapy technique that uses computer software, CT or MRI-based planning, multiple shaped treatment fields, and a multileaf collimator.

Beam modulationThe technique modulates the intensity of overlapping radiation beams projected on the target.

Policy Summary

PayerRegence BlueCross Blue Shield

PolicyIntensity Modulated Radiotherapy (IMRT) for Breast Cancer

Policy CodePolicy 166

Change TypeNo material change

Effective DateJanuary 1, 2026

Last ReviewDec 1, 2025

Next Review DateSeptember 1, 2026

Key ActionSubmit prior authorization for breast cancer IMRT with documentation supporting the applicable medical-necessity pathway.

SourceLink

On This Page

Conventional fractionation is planned or delivered with more than 16 fractions, with or without 4 to 8 boost treatments, and documentation includes a detailed rationale for the medical necessity of the longer conventional regimen.> 16 fractions

Treatment is post-mastectomy and ALL of the following apply

Treatment is directed to ANY of the following
- The chest wall plus the regional nodes, with any number of fractions.
- The chest wall when regional nodes are NOT to be treated, and ALL of the following apply
  - The fractionation requirement is met by ANY of the following
    Hypofractionation is planned or delivered with no more than 28 treatment fractions, with or without 1 to 5 boost treatments.<= 28 fractions
    Conventional fractionation is planned or delivered with more than 28 treatment fractions, with or without 1 to 5 boost treatments, and documentation includes a detailed rationale for the medical necessity of the longer conventional regimen.> 28 fractions

The 2025 ASTRO/ASCO/SSO PMRT guideline includes IMRT, including VMAT, as an appropriate treatment technique. For PMRT, IMRT is recommended when 3-D conformal radiotherapy cannot achieve treatment goals for target coverage and normal-tissue avoidance.

The 2025 PMRT guideline strongly recommends PMRT for node-positive breast cancer and pT4 tumors; it conditionally recommends PMRT for pT3N0 disease, and conditionally recommends chest-wall or reconstructed-breast radiation for positive surgical margins after mastectomy when there is no other PMRT indication. PMRT is generally not recommended for pT1–2N0 disease, although select patients with multiple unfavorable clinicopathologic features may benefit.

For patients receiving PMRT without breast reconstruction, ASTRO strongly recommends moderate hypofractionation of 266–267 cGy per fraction for 15–16 fractions. For patients with breast reconstruction, moderate hypofractionation is preferred over conventional fractionation.

The 2023 ASTRO PBI guideline strongly recommends IMRT for early-stage invasive breast cancer or ductal carcinoma in situ receiving partial-breast irradiation; other techniques, including 3-D conformal radiotherapy, are also recommended.

When a longer conventional fractionation regimen is planned in a policy context where hypofractionation is preferred, documentation should explain the clinical rationale for choosing the conventional regimen rather than hypofractionation.

Documentation Required

Explain longer fractionation

For longer conventional fractionation after lumpectomy or mastectomy, submit a detailed clinical rationale explaining why a conventional longer regimen was selected instead of moderate- or ultra-hypofractionation.

Documentation Required

Include comparative treatment planning

For Criterion II requests, submit color comparative 3D-versus-IMRT dose/volume histograms and the completed summary analysis demonstrating that published organ-at-risk dose/volume constraints can be met only through IMRT.

Render both planning lines on the same graph when possible to facilitate review.
Complete all components of the provided summary analysis table when using it.
Quality assurance procedures are not required for preauthorization.

Documentation Required

Document the conventional-fractionation rationale

When planning conventionally fractionated IMRT in a clinical context where hypofractionation is preferred, provide a note explaining the clinical rationale for choosing conventional fractionation.

Denial Risk

Verify that criteria are met

IMRT is considered not medically necessary for breast cancer treatment that does not meet the policy criteria. Requests that fail to satisfy an applicable medical-necessity pathway may therefore receive an adverse coverage decision.

Denial Risk

Do not submit incomplete clinical documentation

Failure to submit required provider notes, pathology, imaging, or applicable treatment-planning documentation could affect the review outcome and result in an adverse coverage decision.

Provider consultation and relevant follow-up notes
Relevant pathology reports
Relevant imaging reports
Applicable treatment-planning documentation

Denial Risk

Demonstrate an IMRT-specific advantage

For requests reviewed under Criterion II, demonstrate that IMRT is needed to meet applicable dose constraints that cannot be achieved through 3D planning. The submission must show that published organ-at-risk dose/volume constraints can be met only through IMRT.

Denial Risk

Confirm the applicable clinical circumstances

IMRT for breast cancer may be denied when the patient does not meet the select clinical circumstances identified in the policy criteria. In those situations, IMRT has not been shown to improve net health outcomes over other treatment modalities.

Denial Risk

Provide rationale for conventional fractionation

When hypofractionation is preferred by the policy criteria, conventionally fractionated IMRT is considered not medically necessary if no clinical rationale is provided for selecting the longer regimen.

Planning approachComputer-based inverse planning optimizes beam location, shape, and intensity to meet target-dose goals while limiting dose to adjacent normal tissues and organs at risk.

Partial breast irradiation

DefinitionIrradiation directed to the lumpectomy cavity plus a small safety margin.

Treatment volumeThe treatment is targeted to the lumpectomy cavity and safety margin rather than the entire breast.

Delivery methodsPartial breast irradiation may be delivered using external irradiation techniques or brachytherapy.

Acute radiation dermatitis

Grading scaleAcute radiation dermatitis is graded from 0, indicating no change, to 5, indicating death.

Grade 2Grade 2 includes moderate erythema and patchy moist desquamation, mostly in skin folds.

Grade 3Grade 3 includes moist desquamation in other locations and bleeding with minor trauma.

Whole-breast irradiation (WBI)

DefinitionRadiation directed to the entire breast after breast-conserving surgery.

Treatment scopeWhole-breast irradiation treats the entire breast and may include a subsequent boost to the lumpectomy cavity.

Common hypofractionated scheduleThe whole breast is commonly treated with 40 to 42.5 Gy in 15 to 16 fractions.

Partial-breast irradiation (PBI)

DefinitionRadiation directed primarily to the portion of the breast surrounding the tumor bed after breast-conserving surgery.

Alternative to WBIPartial-breast irradiation is used as an alternative to whole-breast irradiation.

Common regimenPartial breast treatment is commonly delivered as 30 Gy in five fractions.

DIBH

Full termDIBH means deep inspiration breath hold.

PurposeDIBH is evaluated with IMRT to reduce cardiac and pulmonary exposure during breast or chest-wall radiotherapy.

Clinical contextThe technique has been studied for treatment involving the left breast or chest wall and regional nodal areas.

Hypofractionation

DefinitionA radiation schedule using fewer treatment sessions with higher doses per session.

Dose adjustmentThe total dose is adjusted through biologic modeling to provide comparable biologic effectiveness.

Treatment outcomesComparable biologic effectiveness is considered in relation to local control, toxicity risk, and cosmetic outcome.

Moderate hypofractionation

DefinitionModerate hypofractionation for postmastectomy radiation without breast reconstruction.

Dose per fractionThe schedule uses 266-267 cGy per fraction.

Number of fractionsThe schedule uses 15-16 fractions.

VMAT

Full termVMAT means volumetric modulated arc therapy.

Relationship to IMRTVMAT is included with IMRT as an appropriate technique for postmastectomy radiation.

When appropriateIMRT, including VMAT, is recommended when 3-D conformal radiotherapy cannot achieve treatment goals for target coverage and normal-tissue avoidance.